Clin2
NCT06922565Possibly a fitNot yet recruiting

Acupuncture for moderate to severe eczema

Atopic Dermatitis

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests whether acupuncture can help people with moderate-to-severe atopic dermatitis (eczema) feel less itchy. If you have persistent itch and are between 18 and 75 years old, you may qualify.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
110 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have been diagnosed with moderate to severe atopic dermatitis (eczema).
  • You are between 18 and 75 years old.
  • Your worst itch in the last 24 hours is at least a 4 out of 10 on a standard rating scale.
  • You are willing to try acupuncture and not currently using certain medications for eczema.
  • You are not pregnant or breastfeeding, and you have not had acupuncture before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07054736Not yet recruiting· Phase 2
Testing XKH001 injection for moderate to severe eczema

This study tests an injected medicine called XKH001 for adults with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if it can reduce itching and skin symptoms.

Hangzhou, Zhejiang
NCT07377838Not yet recruiting· Phase 3
Stem cell injection for moderate to severe eczema

This trial tests a new stem cell injection called ADSTEM for people with moderate to severe eczema that hasn't improved with standard treatments. The goal is to see if it can reduce eczema symptoms like itching, redness, and skin rash.

NCT06487000Not yet recruiting· Phase 2
Testing EC-18 for moderate to severe eczema

This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.

NCT07015762Recruiting· Phase 1
Testing IBI3002 for moderate-to-severe eczema

This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.

Suzhou, Jiangsu
NCT07399067Recruiting· Phase 2
Testing IBI3002 for moderate to severe eczema

This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.

Beijing, Beijing Municipality
NCT06775860Recruiting· Phase 3
Testing ICP-332 for moderate to severe eczema

This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.

Hefei, Anhui

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.